Metvix Daylight PDT in Actinic Keratosis

NCT ID: NCT02674048

Last Updated: 2021-02-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

406 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-09-30

Study Completion Date

2016-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prospective non-interventional study conducted in Australia, Brazil, Mexico and Europe to evaluate clinical practice with Metvix Daylight PDT in the treatment of mild to moderate actinic keratosis of the face/scalp and to assess physician and patient satisfaction.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Actinic Keratosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Metvix

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients to whom Metvix® Daylight-PDT has already been prescribed by their physician, according to the local label;
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Parexel

INDUSTRY

Sponsor Role collaborator

Galderma R&D

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

See Jo-Ann

Sydney, New South Wales, Australia

Site Status

France

Pontoise, , France

Site Status

Italy

L’Aquila, , Italy

Site Status

Alkmaar

Alkmaar, , Netherlands

Site Status

Madrid

Madrid, , Spain

Site Status

Bern

Bern, , Switzerland

Site Status

Manchester

Manchester, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Australia France Italy Netherlands Spain Switzerland United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

See JA, Gebauer K, Wu JK, Manoharan S, Kerrouche N, Sullivan J. High Patient Satisfaction with Daylight-Activated Methyl Aminolevulinate Cream in the Treatment of Multiple Actinic Keratoses: Results of an Observational Study in Australia. Dermatol Ther (Heidelb). 2017 Dec;7(4):525-533. doi: 10.1007/s13555-017-0199-9. Epub 2017 Sep 13.

Reference Type DERIVED
PMID: 28905294 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RD.03.SPR.104956

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

New Treatments for Actinic Keratoses of the Scalp
NCT05456334 ACTIVE_NOT_RECRUITING NA